AROA Biosurgery Partners with Mölnlycke to Co-Promote Endoform in US Post-Acute Care Market

The Quick Take

• AROA Biosurgery and Mölnlycke Healthcare have entered an exclusive agreement to co-promote Endoform in US post-acute care settings
• The partnership gives AROA Biosurgery access to Mölnlycke's extensive US sales network while providing Mölnlycke a competitive wound care product for its portfolio
• Endoform is AROA's soft tissue regeneration product derived from ovine (sheep) extracellular matrix technology used in complex wound management

AROA Biosurgery's exclusive co-promotion agreement with Mölnlycke Healthcare for the Endoform product in US post-acute care settings represents a strategically important commercial development for the New Zealand-based medical device company. Post-acute care settings—skilled nursing facilities, rehabilitation hospitals, long-term acute care facilities—are a high-volume environment for complex wound management, a market where patients with chronic conditions like diabetes, vascular disease, and pressure injuries require advanced wound care products. Endoform's extracellular matrix (ECM) technology addresses this market by providing a scaffold that supports tissue regeneration rather than simply covering wounds.

Mölnlycke's commercial network in the US healthcare system provides AROA with a sales force scale that a company of its size (listed on ASX) could not independently finance. MedTech co-promotion agreements of this type—where a smaller innovator partners with an established distributor in a specific care setting—allow both parties to optimize their comparative advantages: AROA maintains IP ownership and manufacturing while Mölnlycke contributes market access. The exclusivity component of the agreement signals Mölnlycke's commitment to differentiating its wound care portfolio with Endoform's biologic technology versus competitive ECM products from companies like Integra LifeSciences and MiMedx.

The US post-acute care wound management market has been a focus of payer scrutiny due to historical reimbursement abuse in the biologic wound care segment. Centers for Medicare & Medicaid Services (CMS) has repeatedly adjusted reimbursement policies for skin substitutes and ECM products in outpatient and post-acute settings. AROA and Mölnlycke will need to navigate this regulatory reimbursement environment carefully to drive volume growth. Watch for AROA Biosurgery's next earnings call (NZX-listed, ASX-listed ARX) for initial commercial milestones under the Mölnlycke agreement, and for any CMS policy updates affecting ECM product reimbursement in post-acute settings.

Synthesized from 1 source.